No Data
No Data
Aprea Therapeutics Provides Update on Existing Patent Portfolio
Express News | Aprea Therapeutics Announces Strategic Ip Portfolio Evolution in DNA Damage Response (Ddr) Cancer Therapeutics
Strategic Advancements and Financial Stability Drive Buy Rating for Aprea Therapeutics
H.C. Wainwright Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $20
Aprea Therapeutics' Promising ATRN-119: A Buy Rating Amid Optimized Dosing and Safety Advancements
Aprea Therapeutics Announces First Patient Dosed in ABOYA-119 Phase 1/2a Trial
Unlock the Full List